Literature DB >> 3945050

Reliability and stability of the thymidine labeling index of breast carcinoma.

J S Meyer, R W McDivitt.   

Abstract

We have approached the question of the reliability of the thymidine labeling index (TLI) of breast carcinoma by comparing paired samples. Because the distribution of the TLI is approximately lognormal, comparisons were made after transformation to the natural logarithm. For 38 paired samples from the primary carcinoma (biopsy versus residual tumor in mastectomy specimen), r, 0.89, p less than 0.0001. For 68 primary carcinomas versus their axillary metastases, r, 0.90, p less than 0.0001. Substantial correlation was also observed between the TLIs of 18 primary breast carcinomas and their recurrent or metastatic lesions studied after relapse (r, 0.75, p less than 0.0003), and between 14 pairs of first and second primary carcinomas recovered from the same breast (r, 0.72, p less than 0.003). Good agreement was achieved among three observers in measuring the TLI from a set of breast carcinoma autoradiographs. We conclude that the TLI is sufficiently reliable for semiquantitative use as a means of separating breast carcinomas into groups with slow, moderate, and rapid rates of proliferation. The substantial similarities between the TLIs of breast carcinoma samples from different sites of the primary tumor, between primary tumor and axillary metastases, and between primary tumor and subsequent samples of relapsed tumor suggest that clonal evolution either is infrequent or does not usually affect the cell kinetics of the carcinoma. The similarity of the TLIs of synchronous dual primary carcinomas is an additional interesting finding.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3945050

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  8 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer.

Authors:  L C Chen; A Neubauer; W Kurisu; F M Waldman; B M Ljung; W Goodson; E S Goldman; D Moore; M Balazs; E Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

3.  Cancer biology for individualized therapy: correlation of growth fraction index in native-state histoculture with tumor grade and stage.

Authors:  R A Vescio; K M Connors; T Youngkin; G M Bordin; J A Robb; J N Umbreit; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

4.  Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors.

Authors:  J S Meyer; M Province
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872

Review 5.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

6.  Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma.

Authors:  A Bonetti; M Zaninelli; S Rodella; A Molino; L Sperotto; Q Piubello; F Bonetti; R Nortilli; M Turazza; G L Cetto
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

7.  Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis.

Authors:  M Rudas; M F Gnant; M Mittlböck; R Neumayer; A Kummer; R Jakesz; G Reiner; A Reiner
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 8.  Measuring proliferation in breast cancer: practicalities and applications.

Authors:  Mark J Beresford; George D Wilson; Andreas Makris
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.